Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow ...

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

Multiple myeloma, historically treated as a single ... Advances in molecular testing, such as cytogenetic analysis of plasma cells, have allowed clinicians to stratify patients based on risk ...

Treated with a dexamethasone-sparing regimen, frail older adult patients with newly diagnosed multiple myeloma (MM ... cancer stage, cytogenetics, and creatinine clearance; however, those with ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Cytogenetic results revealed that 64% of ... robust evidence for this strategy after salvage HSCT in relapsed multiple myeloma. Unlike the GMMG ReLApsE study, which found no PFS benefit for ...

"We have seen how immunotherapy added to existing backbones can improve outcomes in multiple myeloma ... with the exception of those with high-risk cytogenetic features (HR 0.97, 95% CI 0.48-1. ...

Blenrep won accelerated FDA approval in 2020 as a fourth-line or later treatment for multiple myeloma, but was withdrawn from sale following the failure of the DREAMM-3 study in 2020 to show an ...